- Visibility 116 Views
- Downloads 107 Downloads
- Permissions
- DOI 10.18231/j.ctppc.v.7.i.3.2
-
CrossMark
Exploring Terminalia arjuna for in-vitro antibacterial, antifungal and in-silico antibacterial, antiviral properties
- Author Details:
-
Lalit Samant *
-
Dhruv Mamtora
-
Sonal Patil
-
Khusbhu Dalvi
-
Minnie Bodhanwala
Lalit Samant *
Dhruv Mamtora
Human Cytomegalovirus (HCMV) poses a significant threat to immunocompromised individuals, with current antiviral agents such as ganciclovir, valganciclovir, foscarnet, and cidofovir facing increasing resistance due to mutations in viral genes like UL97 and UL54. This study explores the potential of ellagic acid, a major bioactive compound in Terminalia arjuna bark extract, as an alternative antiviral agent targeting HCMV protease, a critical enzyme in viral replication. Molecular docking simulations revealed a strong binding affinity of ellagic acid to HCMV protease, suggesting its ability to inhibit viral replication. Additionally, in vitro antimicrobial assays demonstrated significant activity against Methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus faecalis, while antifungal activity against Candida albicans was weaker. Docking studies further showed ellagic acid interacting with key bacterial resistance mechanisms, including the fosfomycin-resistant gene in Klebsiella pneumoniae. These findings highlight T. arjuna extract, particularly ellagic acid, as a promising candidate for combating HCMV and antibiotic-resistant infections, with potential applications in immunocompromised patients.
References
- Erice A. Resistance of Human Cytomegalovirus to Antiviral Drugs. Vol. 12. 1999. 91 Samant et al / Current Trends in Pharmacy and Pharmaceutical Chemistry 2025;7(3):87-91
- Chaer F El, Shah DP, Chemaly RF. How I Treat How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. 2016; Available from: http://ashpublications.org/blood/article- pdf/128/23/2624/1397134/blood688432.pdf
- Devi A, Devi P. Emerging Therapeutic properties of Terminalia Arjuna: A Review Designation: Lecturer 1 and Bsc student 2. 2024. Available from: www.ijnrd.org
- Golmei P, Kasna S, Roy KP, Kumar S. A Review on Pharmacological Advancement of Ellagic Acid. J Pharmacol Pharma. 2024;15:93–104.
- Cao-Ngoc P, Leclercq L, Rossi JC, Hertzog J, Tixier AS, Chemat F, et al. Water-based extraction of bioactive principles from blackcurrant leaves and chrysanthellum americanum: A comparative Study. Foods. 2020;9(10):1478.
- Tomich AD, Klontz EH, Deredge D, Barnard JP, McElheny CL, Eshbach ML. et al. Small-molecule inhibitor of FosA expands fosfomycin activity to multidrug-resistant Gram-negative pathogens. Antimicrob Agents Chemother. 2019;63(3): e01524-18.
- Das M, Bickers DR, Mukhtar H. Plant phenols as invitro inhibitors of glutathione S-transferase(s). Biochem Biophys Res Commun. 1984;120(2):427–33.
- Ilangovan A, Fletcher M, Rampioni G, Pustelny C, Rumbaugh K, Heeb S. et al. Structural Basis for Native Agonist and Synthetic Inhibitor Recognition by the Pseudomonas aeruginosa Quorum Sensing Regulator PqsR (MvfR). PLoS Pathog. 2013;9(7):e1003508
- Lynch K. The importance of drug exposure in the development of drug-resistant CMV. Antiviral Res. 2025;[Epub ahead of print]. Subtherapeutic antiviral drug levels often lead to resistant CMV strains, contributing to disease progression. ScienceDirect
- Horsten F, Gillemot S, Dorval S, Ho G, Maes P, Snoeck R, Andrei G. Emergence of antiviral drug resistance in congenital cytomegalovirus infection during treatment: updated review and case report. Pediatr Infect Dis J. 2025; 1097
- Kleiboeker SB. Dual resistance to maribavir and ganciclovir in transplant-associated CMV infection. J Clin Virol. 2025;17(3):421.
- Carter MF. Generation of a panel of CMV mutants resistant to ganciclovir, maribavir, cidofovir, and letermovir. Antiviral Res. 2025; 106237.
- Toti L, Kamar N, Alain S, Manuel O, Basic-Jukic N, Grossi PA. et al. Advancements in CMV management among solid-organ transplant recipients: insights from the ESOT CMV Workshop 2023. Transpl Int. 2025;38:14195.
- Rolsdorph LÅ. New cytomegalovirus antiviral therapy: potential prevention and treatment of CMV-induced hemophagocytic lymphohistiocytosis (HLH). Expert Opin Investig Drugs. 2025; 26(3):231-4.
- Pinchera B, Carrano R, Gigliotti G, Salemi F, Agostino A, Vitiello F. et al. Two cases of maribavir treatment for refractory/resistant CMV infection in solid-organ transplant recipients: time for a new paradigm?. Exp Clin Transp. 2025;23(4):306–09.
- Chou S. Comparative emergence of maribavir and ganciclovir resistance: concern over the lower genetic barrier of newer antivirals. J Infect Dis. 2025;231(3):e470.
- Yao Y, Zeng Q, Sun Y, Jin E, Tang J, Cai Y. et al. A novel strategy for management of CMV retinitis in immunocompromised patients using letermovir and/or maribavir. Front Med. 2025;11:1-8.
- Chung H. CMV infections after HSCT: Prophylaxis and treatment. Bone Marrow Transplant. 2025:60(1):33.